ADVERUM BIOTECHNOLOGIES INC (ADVM)

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on November 17, 2024, the...

Adverum Biotechnologies Becomes Oversold (ADVM)

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

– Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18th at 7:30 a.m. EST REDWOOD CITY, Calif., Nov. ...

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

- 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial...

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a company pioneering the use of gene therapy as a...

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on September 3, 2024, the...

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of...

ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q2 2024

ADVM stock results show that Adverum Biotechnologies beat analyst estimates for earnings per share the second quarter of 2024.

ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adverum Biotechnologies (NASDAQ:ADVM) just reported results for the second quar...

Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

- 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class...

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

REDWOOD CITY, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene...

Friday 7/19 Insider Buying Report: ADVM, BHVN

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

-   6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile...

Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene...

Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors

REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene...

ADVM Stock Earnings: Adverum Biotechnologies Misses EPS for Q1 2024

ADVM stock results show that Adverum Biotechnologies missed analyst estimates for earnings per share the first quarter of 2024.

ADVM Stock Earnings: Adverum Biotechnologies Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adverum Biotechnologies (NASDAQ:ADVM) just reported results for the first quart...

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene...

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of...

ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023

ADVM stock results show that Adverum Biotechnologies beat analyst estimates for earnings per share the fourth quarter of 2023.

ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Adverum Biotechnologies (NASDAQ:ADVM) just reported results for the fourth quar...

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety...

Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop

There are plenty of penny stocks ready to pop but we have to remember that penny stocks are extremely risky, too.

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene...

Stocks on the Launchpad: The Next 3 Market Sensations

Navigate the bullish trend in the market by wagering on these three enticing market sensations likely to become multi-bagger investments

Unleash Massive Returns With These 3 Top Penny Stocks

Our economy is doing well, and these top penny stocks are in position to benefit from this. Invest now and see strong returns.

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction...

Monday Sector Leaders: Biotechnology, Semiconductors

Adverum Biotechnologies announces $127.5M private placement financing (NASDAQ:ADVM)

Adverum Biotechnologies plans to raise $127.5 million by selling approximately 106.25 million shares of its common stock in a private placement.